Boxer Capital Management
Latest statistics and disclosures from Boxer Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are TNGX, KOD, RVMD, KYMR, CELC, and represent 50.04% of Boxer Capital Management's stock portfolio.
- Added to shares of these 10 stocks: PCVX (+$19M), CRVS (+$16M), DFTX (+$11M), VIR (+$11M), IRD (+$10M), SRZN (+$10M), CORT (+$10M), RVMD (+$9.7M), KOD (+$8.6M), ABVX (+$8.4M).
- Started 13 new stock positions in RGNX, Soleno Therapeutics, ALLO, CRVS, OCUL, RLMD, CORT, ORIC, IRD, Crescent Biopharma. ANTX, DFTX, PCVX.
- Reduced shares in these 7 stocks: CDTX (-$12M), MNMD (-$8.0M), CBIO (-$5.4M), HELP, PEPG, NUVB.WS, INO.
- Sold out of its positions in CDTX, MNMD, NUVB.WS, CBIO.
- Boxer Capital Management was a net buyer of stock by $157M.
- Boxer Capital Management has $762M in assets under management (AUM), dropping by 66.71%.
- Central Index Key (CIK): 0002018299
Tip: Access up to 7 years of quarterly data
Positions held by Boxer Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Boxer Capital Management
Boxer Capital Management holds 54 positions in its portfolio as reported in the March 2026 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Tango Therapeutics (TNGX) | 29.9 | $228M | 11M | 20.92 |
|
|
| Kodiak Sciences (KOD) | 6.8 | $52M | +19% | 1.4M | 38.12 |
|
| Revolution Medicines (RVMD) | 6.4 | $49M | +25% | 500k | 97.25 |
|
| Kymera Therapeutics (KYMR) | 3.6 | $27M | 329k | 83.29 |
|
|
| Celcuity (CELC) | 3.4 | $26M | 225k | 114.14 |
|
|
| Surrozen Com New (SRZN) | 2.9 | $22M | +84% | 766k | 29.13 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.9 | $22M | +60% | 200k | 111.35 |
|
| Terns Pharmaceuticals (TERN) | 2.6 | $20M | 375k | 52.72 |
|
|
| Vaxcyte (PCVX) | 2.5 | $19M | NEW | 325k | 58.11 |
|
| Capricor Therapeutics Com New (CAPR) | 2.4 | $18M | +81% | 590k | 30.40 |
|
| Protagonist Therapeutics (PTGX) | 2.4 | $18M | 170k | 105.40 |
|
|
| Vir Biotechnology (VIR) | 2.2 | $17M | +198% | 1.9M | 8.96 |
|
| Corvus Pharmaceuticals (CRVS) | 2.1 | $16M | NEW | 1.1M | 14.63 |
|
| Praxis Precision Medicines I Com New (PRAX) | 2.0 | $15M | 47k | 322.19 |
|
|
| Ptc Therapeutics I (PTCT) | 1.8 | $14M | 200k | 68.13 |
|
|
| Precigen (PGEN) | 1.8 | $14M | +154% | 3.5M | 3.87 |
|
| Definium Therapeutics Com Shs (DFTX) | 1.5 | $11M | NEW | 599k | 18.90 |
|
| Amylyx Pharmaceuticals (AMLX) | 1.5 | $11M | 800k | 13.90 |
|
|
| Uniqure Nv SHS (QURE) | 1.4 | $11M | +128% | 662k | 16.35 |
|
| Ocuphire Pharma (IRD) | 1.3 | $10M | NEW | 2.3M | 4.55 |
|
| Corcept Therapeutics Incorporated (CORT) | 1.3 | $10M | NEW | 250k | 40.31 |
|
| Urogen Pharma (URGN) | 1.2 | $9.0M | 500k | 17.98 |
|
|
| Replimune Group (REPL) | 1.2 | $9.0M | +56% | 1.2M | 7.65 |
|
| Cogent Biosciences (COGT) | 1.1 | $8.7M | 225k | 38.49 |
|
|
| Palisade Bio (PALI) | 1.1 | $8.4M | 4.8M | 1.75 |
|
|
| Crescent Biopharma | 1.1 | $8.3M | NEW | 454k | 18.37 |
|
| Soleno Therapeutics | 0.9 | $6.7M | NEW | 200k | 33.48 |
|
| Allogene Therapeutics (ALLO) | 0.9 | $6.6M | NEW | 2.7M | 2.44 |
|
| Cytokinetics Com New (CYTK) | 0.9 | $6.6M | 100k | 65.91 |
|
|
| Contineum Therapeutics Cl A (CTNM) | 0.8 | $6.5M | 494k | 13.06 |
|
|
| Apogee Therapeutics (APGE) | 0.8 | $5.9M | 70k | 84.17 |
|
|
| Relmada Therapeutics (RLMD) | 0.8 | $5.9M | NEW | 842k | 6.96 |
|
| Zura Bio Class A Ord Shs (ZURA) | 0.7 | $5.4M | +1700% | 900k | 5.95 |
|
| Moonlake Immunotherapeutics Class A Ord (MLTX) | 0.7 | $5.1M | 275k | 18.64 |
|
|
| Avalo Therapeutics Com New (AVTX) | 0.6 | $4.5M | +9% | 300k | 14.93 |
|
| Inovio Pharmaceuticals Com Shs (INO) | 0.5 | $4.1M | -2% | 2.4M | 1.74 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 0.5 | $3.6M | 75k | 48.20 |
|
|
| Sarepta Therapeutics (SRPT) | 0.4 | $3.3M | 150k | 21.76 |
|
|
| Cybin Com New (HELP) | 0.4 | $3.1M | -10% | 640k | 4.80 |
|
| Ocular Therapeutix (OCUL) | 0.4 | $3.0M | NEW | 350k | 8.47 |
|
| An2 Therapeutics (ANTX) | 0.3 | $2.6M | NEW | 749k | 3.42 |
|
| Clene Com New (CLNN) | 0.3 | $2.4M | +139% | 478k | 4.93 |
|
| Oric Pharmaceuticals (ORIC) | 0.3 | $2.2M | NEW | 177k | 12.67 |
|
| Solid Biosciences Com New (SLDB) | 0.3 | $2.2M | 300k | 7.20 |
|
|
| Adagio Therapeutics (IVVD) | 0.3 | $2.0M | 1.5M | 1.30 |
|
|
| Lb Pharmaceuticals Com Shs (LBRX) | 0.2 | $1.7M | 70k | 24.66 |
|
|
| Karyopharm Therapeutics Com New (KPTI) | 0.2 | $1.7M | +19% | 303k | 5.57 |
|
| Nurix Therapeutics (NRIX) | 0.2 | $1.6M | 100k | 15.50 |
|
|
| Upstream Bio (UPB) | 0.2 | $1.4M | 150k | 9.00 |
|
|
| Milestone Pharmaceuticals (MIST) | 0.1 | $793k | 667k | 1.19 |
|
|
| Pepgen (PEPG) | 0.1 | $483k | -27% | 273k | 1.77 |
|
| Kalvista Pharmaceuticals | 0.1 | $411k | 20k | 20.13 |
|
|
| Regenxbio Inc equity us cm (RGNX) | 0.0 | $126k | NEW | 15k | 8.38 |
|
| Surrozen *w Exp 08/01/203 (SRZNW) | 0.0 | $1.1k | 67k | 0.02 |
|
Past Filings by Boxer Capital Management
SEC 13F filings are viewable for Boxer Capital Management going back to 2024
- Boxer Capital Management 2026 Q1 filed May 15, 2026
- Boxer Capital Management 2025 Q1 restated filed Feb. 17, 2026
- Boxer Capital Management 2025 Q2 restated filed Feb. 17, 2026
- Boxer Capital Management 2025 Q3 restated filed Feb. 17, 2026
- Boxer Capital Management 2025 Q4 filed Feb. 17, 2026
- Boxer Capital Management 2025 Q3 filed Nov. 14, 2025
- Boxer Capital Management 2025 Q2 filed Aug. 14, 2025
- Boxer Capital Management 2025 Q1 filed May 15, 2025
- Boxer Capital Management 2024 Q4 filed Feb. 14, 2025